Tissue and Plasma Pharmacokinetics of Cefazolin in Antibiotic Prophylaxis in Bariatric Surgery
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
With 6.5 million obese recorded in France in 2009, obesity is a major public health: it is a
chronic disease associated with many respiratory, cardiac, metabolic, musculoskeletal
complications. The risk of mortality and morbidity are directly proportional to the
importance of overweight and medical treatment alone is only moderately effective weight
loss. Bariatric surgery is the only treatment with proven efficacy in patients with a body
mass index above 40 kg/m2. As with any surgery, there is a risk of surgical site infection
(SSI). The SSI are the third most common nosocomial infection after urinary tract infections
and airway. The fight against the ISO requires the administration of antibiotic prophylaxis
acting on the main bacteria found in bariatric surgery. There are several studies in the
literature interested in the dose of cefazolin in bariatric surgery. However, no published
pharmacokinetic studies defines an optimal dose to obtain tissue and plasmatic concentrations
of cefazolin higher than minimum inhibitory concentrations of the main germs encountered in
these surgery. Only empirical recommendations are published, including the SFAR and the
National Institute of Health in 2010. This study aims to determine whether the dose of 4
grams of cefazolin can achieve these goals of concentration and estimate an injection time of
preoperative ideal for an adequate tissue concentration at the time of the incision.